Rối loạn lipid máu hỗn hợp. Hiện tại và những thách thức

1. The International Atherosclerosis Society: An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia. Full report. http://www.athero.org/download/ IASPPGuidelines_FullReport_20131011.pdf

2. Fruchart JC et al. Residual macrovascular risk in 2013: what have we learned? Cardiovascular Diabetology

, 13:26

3. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D, ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees: ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818

4. StoneNJ,RobinsonJ,LichtensteinAH,MerzCN,BlumCB,EckelRH,GoldbergAC,GordonD,Levy D, Lloyd- Jones DM, McBrideP, SchwartzJS, SheroST, SmithSCJr, WatsonK, WilsonPW.2013ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults:A Report of the American College of Cardiology/American Heart Association Task Force on Practice. Guidelines.Circulation2013[Epubaheadofprint].

5. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation106,3143-3421 (2002).

6. American Association of Clinical Endocrinologist’s guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis ..Endocr Pratic 2012 ;18 supl 1

7. Boekholdt SM, Arsenault BJ, Mora S et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta- analysis. JAMA307,1302-1309 (2012).

8. Barter P, Gotto AM, LaRosa JC et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med.357,1301-1310 (2007).

9. Guyton JR, Slee AE, Anderson T, Fleg JL, Goldberg RB, Kashyap ML, Marcovina SM, Nash SD, O’Brien KD, Weintraub WS, Xu P, Zhao XQ, Boden WE: Relationship of lipoproteins to cardiovascular events. The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). J Am Coll Cardiol 2013, 62:1580-1584.

10. HPS2-THRIVE Collaborative Group: HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013, 34:1279-1291.

11.Cannon CP, Giugliano RP, Blazing MA, et al. IMPROVE-IT Investigators Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008;156:826-832

12. ACCORD Study Group. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus [Erratum in N Engl J Med. 2010;6;362:1748]. N Engl J Med. 2010;362:1563- 1574

13. Elam M, Lovato LC, Ginsberg H. Role of fibrates in cardiovascular disease prevention, the ACCORD- Lipid perspective. Curr Opin Lipidol. 2011;22:55-61

14. Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis. 2011;217:492-498

15. Sacks FM, Carey VJ, Fruchart JC: Combination lipid therapy in type 2 diabetes. N Engl J Med 2010, 363:692-684

16. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Japan EPA lipid intervention study (JELIS) Investigators: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis.Lancet 2007, 369:1090-1098.

17. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS: Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012, 308:1024-1033.

18. Raymond C, Cho L, Rocco M, Hazen SL. New cholesterol guidelines: worth the wait? Cleve Clin J Med 2014;81:11-19. Gudzune KA, Monroe AK, Sharma R, Ranasinghe PD, Chelladurai Y, Robinson KA. Effectiveness of Combination Therapy With Statin and Another Lipid-Modifying Agent Compared With Intensified Statin Monotherapy: A Systematic Review. Ann Intern Med 2014. [Epub ahead of print].

20. Smith SC, Grundy SM 2013 ACC/AHA Guideline Recommends Fixed-Dose Strategies Instead of Targeted Goals to Lower Blood Cholesterol. J Am Coll Cardiol 2014;64:601-12.